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Abstract
Obstetric hemorrhage is the leading cause of maternal morbidity and mortality world-
wide. At highest risk of massive obstetric hemorrhage, are women with morbidly adher-
ent placenta (MAP). The complications associated with MAP are even more devastating 
in very high-risk obstetrical patients, where blood transfusion is not an option, either 
due to lack of resources or patient refusal, such as for Jehovah’s Witnesses. Resuscitative 
endovascular balloon occlusion of the aorta (REBOA) is a minimally-invasive technique 
used in trauma surgery to control non-compressible hemorrhage. REBOA is emerging 
as useful tool for managing high-risk obstetric surgery for MAP. This review aims to 
provide a framework for use of REBOA in obstetric care in challenging circumstances.
Keywords: accreta, aortic balloon, balloon occlusion, Jehovah’s Witness, morbidly 
adherent placenta, obstetric hemorrhage, percreta, REBOA
1. Introduction
Obstetric hemorrhage is the leading cause of maternal morbidity and mortality worldwide [1]. 
At highest risk of massive obstetric hemorrhage are women with a morbidly adherent placenta 
(MAP). MAP describes the penetration of placental chorionic villi into the uterus to varying 
degrees classified as—placenta accreta, increta, and percreta. The incidence of MAP is increasing. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In the United States alone, the rate doubled from 5.4 in 10,000 deliveries to 11.9 in 10,000 over a 
period of 6 years [2]. The most severe form, placenta percreta, in which chorionic villi penetrate 
through the uterine wall and into adjacent organs, has increased 50-fold in the last 50 years [3].
Women with multiple prior cesarean deliveries are at greatest risk for MAP. The risk of MAP 
in patients after one, two, or three prior cesarean deliveries increases 2.9, 4.6 and 12.6-fold, 
respectively [4]. Additional risk factors include prior surgical injury to the myometrium, 
including dilation and curettage, and advanced maternal age.
The potential consequences of obstetric hemorrhage are most dire in women who refuse, or can-
not receive, blood products. For example, the maternal mortality ratio (MMR) due to major obstet-
ric hemorrhage in Jehovah’s Witnesses was 68 per 100,000 live births in one study; 130 times that 
of the general population [5]. Furthermore, in low resource settings, where blood products are 
not readily available, the MMR can be up to 645 per 100,000 live births [6]. Obstetric hemorrhage 
accounts for up to 42% of maternal deaths in low resource settings [7]. With this in mind, new 
strategies for obstetric hemorrhage control are essential for improving transfusion-free survival.
Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an emerging, minimally-
invasive technique to control non-compressible hemorrhage. Although initially developed 
for the management of traumatic hemorrhage, REBOA has been gaining popularity for the 
control of non-traumatic hemorrhage. Early reports of REBOA use in obstetric hemorrhage 
indicate that the approach reduces blood loss, improves maternal outcomes, and decreases 
rates of hysterectomy compared to traditional techniques, such as uterine balloon tamponade, 
and hypogastric or uterine artery occlusion [8–10]. This review describes the potential appli-
cations of REBOA for control of obstetric hemorrhage in high-risk obstetric surgery for MAP.
High-quality evidence to inform management of obstetric hemorrhage when transfusion is 
not an option is generally lacking. Small numbers of patients, clinical heterogeneity, and ethi-
cal principles preclude against randomized studies, so most data are drawn from case series 
and case reports, as well as from physiological principles and expert opinions. REBOA is a 
growing modality with novel applications, as well as technical and technological improve-
ments that are continually evolving. The application of REBOA to obstetric hemorrhage is in 
its infancy, thus comparative data and long-term follow-up are lacking. While this may limit 
the strength of any generalizations that can be drawn from the literature, this review aims 
to provide a framework for use of REBOA in obstetric care in this challenging circumstance.
2. Demographics of high-risk patients
Approximately 60% of women with MAP will experience significant morbidity, including 
blood transfusion, urologic injury, infection, intensive care unit admission, and readmis-
sion. A 15% of obstetric hemorrhage requiring blood transfusion are due to MAP [11]. The 
majority of patients with MAP will undergo invasive procedures, have extensive blood loss 
and require massive blood transfusion [2, 11]. A 90% of patients with placenta percreta who 
undergo cesarean hysterectomy will require blood transfusion due to intraoperative blood 
losses greater than three liters, with median transfusion of 7 units of red blood cells [12, 13]. 
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The morbidity and mortality associated with MAP is even more devastating when blood 
transfusion is not an option, either from lack of resources or patient refusal. Patients decline 
blood transfusions for a variety of reasons, most commonly due to religious grounds, such as 
for Jehovah’s Witnesses. For these patients, the risk of mortality due to obstetric hemorrhage 
is 130 times greater than in the normal population [5].
3. Traditional hemorrhage mitigation strategies
3.1. Preoperative optimization
During the first prenatal visit, willingness to accept blood products should be addressed and 
alternatives to transfusion discussed. For patients who indicate that they would not accept 
blood transfusion, providers should investigate which, if any, blood products or alternatives 
may be acceptable in the case of an emergency. In addition to establishing patient capacity, 
a thorough discussion of the potential risks and benefits of transfusion is necessary. This 
discussion with patients should be performed privately and confidentially. It must be free of 
coercion and judgment from outside parties [14, 15]. In circumstances of a religious basis for 
blood refusal, patients frequently consult with religious leaders, family and friends prior to 
making a decision, but the final decision must rest in the hands of the patient herself. These 
discussions must be clearly documented in the medical record.
Preoperative optimization of hemoglobin by treating underlying anemia is ideal. Many patients 
who do not accept blood will accept other methods to improve hemoglobin levels. Iron, vitamin 
B12, folate and recombinant erythropoietin can be used preoperatively [14, 15]. Intravenous iron 
is preferred over oral preparations because of faster and more reliable increases in hemoglobin. 
Recombinant erythropoietin can optimize hemoglobin both preoperatively and postoperatively. 
However, there are no clear guidelines on optimal dosing. While studies suggest erythropoietin 
is safe to use in pregnancy, it can increase the risk of venous thromboembolism (VTE), which 
may exacerbate an already hypercoagulable state [16]. Consultation and coordination with a 
hematologist should be considered.
As the pregnancy advances, careful monitoring of the placenta is imperative to understand-
ing the extent of MAP. A plan for delivery in an appropriately-resourced setting is crucial. 
Advanced directives should be established, with legal counsel as necessary. A multidisci-
plinary effort should be assembled to discuss the optimal approach to planned and unplanned 
delivery. Ideally, this team should include members of the surgical obstetric team (which 
may include gynecologic oncology), maternal fetal medicine, neonatology, anesthesia, and 
in-house emergency surgery providers (such as trauma or vascular surgery) as indicated. 
Working with risk management, social services, and the ethics board may be necessary to 
optimize outcomes in these complex, high-risk situations.
3.2. Intraoperative adjuncts
Minimization of intraoperative blood loss and optimization of anemia tolerance improves 
outcomes. While the surgical team focuses on hemostatic techniques to decrease blood loss, 
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the anesthesia team can also support this goal. Patient positioning and ventilation mode can 
alter venous congestion, venous preload, cardiac output and peripheral vascular resistance. 
Normothermia aids in hemostasis. Additionally, intentional hypotension after delivery of the 
fetus may help minimize blood loss. A more detailed description of the anesthetic management 
of patients with MAP is beyond the scope of this article and has been covered elsewhere [16].
Several other methods can improve physiologic tolerance of anemia. Intraoperative volume 
expansion can be achieved through acute normovolemic hemodilution (ANH). With ANH, 
venous blood is removed into citrated bags at the start of surgery. The blood remains in a 
closed circuit with the patient throughout surgery. Crystalloid is administered to increase 
blood volume until hemorrhage is controlled, at which point ANH blood is transfused [17, 18]. 
Survival after more than five liters of blood loss has been documented in Jehovah’s Witness 
patients with placenta percreta using ANH and cell salvage [19].
There is variability in the products that Jehovah’s Witnesses will and will not accept [15]. 
Generally, whole blood products are prohibited, but some patients will accept fractions, such as 
hemoglobin, albumin, cryoprecipitate, clotting factors and platelets. A study of Jehovah’s Witness 
patients found that, although most would decline conventional blood products, 76% would 
accept other blood components [20]. Most will accept crystalloid, colloid, recombinant factor VIIa 
(rFVIIa), factor VIII (FVIII), fibrinogen, tranexamic acid (TXA), and artificial blood substitutes 
[14, 15], but use of individual blood components alone may have limitations. Cryoprecipitate, 
containing FVIII, factor XIII (FXIII), von Willebrand factor (vWF) and fibrinogen, can be used in 
a postpartum hemorrhage to reduce risk of coagulopathy due to hypofibrinogenemia. However, 
it is not a substitute for plasma due to the lack of other coagulation factors. There is limited 
evidence that rFVIIa is helpful in refractory postpartum hemorrhage [21]. Finally, TXA is an anti-
fibrinolytic agent that can be an adjunct for hemorrhage management. A Cochrane review found 
that TXA decreases blood loss and hemorrhage in both vaginal and cesarean deliveries [22]. The 
WOMAN trial found that administering TXA for postpartum hemorrhage within 3 hours of 
delivery decreased the rate of death due to bleeding compared to placebo. The authors found no 
difference in adverse events, including VTE, organ failure, sepsis, and seizure. They also found 
no difference in the rates of hysterectomy in both groups [23].
Cell salvage has become an important component of operative hemorrhage management for 
high-risk patients. However, there are important limitations of the cell salvage to consider. Cell 
salvage can only utilize blood collected into the canister, must have a minimum of 500 ml of blood 
before the cells can be washed, and returns at most 50% of the washed blood volume back to the 
patient. Furthermore, this technique does not allow for easy collection of vaginal blood loss, and 
therefore has limited utility in many obstetric hemorrhage cases. Safe use of the cell-saver has 
been demonstrated in obstetric patients, particularly when no future pregnancy is planned [24].
3.3. Traditional invasive hemorrhage control techniques
Definitive management for MAP is to complete a cesarean hysterectomy. A more conservative 
approach is to leave the placenta and uterus in situ after cesarean delivery of the infant. Follow 
up plans include observation with or without methotrexate, delayed hysteroscopic resection 
or interval hysterectomy several weeks later [25, 26]. Although conservative management is 
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successful in 78.4% of cases, this treatment carries an increased risk of postoperative sepsis 
and hemorrhage, which could necessitate emergent hysterectomy, further increasing the risk 
of more serious complications [25, 27]. In patients where the placenta is left in place, a risk 
of bleeding and infection exists for up to 5 months [28]. The risks of this approach may be 
prohibitively high in patients who cannot accept blood transfusion [25].
Traditional vascular methods of hemorrhage control during cesarean hysterectomy include 
intraoperative hypogastric artery ligation, uterine artery balloon occlusion with or without 
embolization, and temporary balloon occlusion of the hypogastric arteries. These methods have 
come under criticism after studies failed to demonstrate a significant reduction in blood loss 
or transfusion volumes compared to cesarean hysterectomy without these measures [29–31].
Ligation of the hypogastric arteries theoretically reduces pulse pressure to the uterus; how-
ever, it is successful in reducing operative blood loss in fewer than 50% of cases. Furthermore, 
ligation is estimated to be even less useful in MAP involving the bladder [32]. The literature 
regarding prophylactic intravascular hypogastric balloon occlusion during cesarean hysterec-
tomy with MAP is mixed. Some studies suggest this technique reduces intraoperative blood 
loss and transfusion requirements [33], but others have found no difference in blood loss even 
in combination with uterine artery embolization, concluding that prophylactic intravascular 
balloon catheters yield no significant benefit [29–31]. These disparate findings are most likely 
explained by the persistent proximal collateral circulation to the uterus which contributes to 
venous hemorrhage during surgery [34, 35].
Aortic cross-clamping can aid in hemorrhage control when hypogastric artery occlusion is 
insufficient [36]. Once surgical hemostasis has been maximized, damage control techniques 
such as packing and temporary abdominal closure may be useful in cases of disseminated 
intravascular coagulation.
3.4. Management of postoperative anemia
Postoperative management centers around reducing further hemorrhage and providing sup-
portive care for profound anemia. Intensive care monitoring may be required. Hematology 
consultation may provide guidance regarding hemoglobin optimization with use of high dose 
erythropoietin, intravenous iron, and other adjuncts [16]. Using pediatric blood collection 
tubes and avoiding unnecessary lab draws are helpful strategies. In extreme cases, measures 
to reduce oxygen demand and increase oxygen delivery, including intubation, sedation, and 
hyperbaric oxygen, may be beneficial [16, 37]. Finally, providers must weigh the risks and 
benefits of anticoagulation causing increased bleeding against the risk of VTE.
4. Novel hemorrhage mitigation strategies
4.1. Resuscitative endovascular balloon occlusion of the aorta (REBOA)
REBOA is a catheter-based alternative to aortic cross clamping that can be used proactively 
prior to hemodynamic collapse and even prior to anticipated hemorrhage. Endoluminal aortic 
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occlusion to control non-compressible torso hemorrhage was first described in 1954 [38]. The 
technique was popularized decades later when advances in endovascular technology made 
catheter-based vascular control more commonplace for repair of aortic aneurysms. Recently, 
the REBOA catheter has been modified to be percutaneous, wireless, and fluoroscopy-free, 
leading to its wider adoption for non-compressible hemorrhage control [39].
Despite advancements in technology, the general principles of performing REBOA have 
remained largely unchanged (Table 1). Most published data about REBOA come from trauma 
literature, but its use in obstetric emergencies and high-risk surgeries is expanding [8–10, 40]. 
Our institution has successfully documented the use of REBOA in a Jehovah’s Witness patient 
with placenta percreta [41]. This section will discuss the unique considerations for performing 
REBOA in the high-risk obstetric patient.
4.2. Benefits
REBOA is an alternative endovascular hemorrhage control technique, which significantly 
reduces obstetric blood loss compared to combined hypogastric and uterine artery occlusion 
[8–10]. Reports of prophylactic REBOA use during MAP procedures demonstrate improved 
maternal outcomes and decreased hysterectomy rates [9]. Compared to uterine or hypogas-
tric artery occlusion techniques, REBOA requires less time for placement and only unilateral 
arterial puncture making it useful in emergent cases (Table 2) [8]. REBOA use has demon-
strated lower transfusion volumes than other occlusion techniques [8]. Furthermore, new 
modifications in REBOA allow placement without fluoroscopy which leads to little to no fetal 
radiation exposure [8, 42–45].
Catheter measurements based on anatomic landmarks can serve as a basis for positioning 
of the balloon within the aorta [39, 46]. The effect of a gravid abdomen on the accuracy of 
• Gain common femoral arterial access
• Position the balloon in the most distal location appropriate for providing adequate hemorrhage control
• Slowly deflate the occlusion balloon when hemodynamics permit
• Remove the catheter and sheath promptly, apply pressure to access site
• Monitor the patient post-operatively for ischemia–reperfusion injury and arterial access site complications
Table 1. Principles of REBOA.
• Single arterial access site, concurrent arterial blood pressure monitoring
• Little to no fetal radiation exposure
• Can be inserted and adjusted in the operating room
• Improved hemostasis compared to hypogastric and/or uterine artery occlusion
• Can be inserted quickly in response to emergent hemorrhage
Table 2. Benefits of REBOA.
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using external landmarks for fluoroscopy-free REBOA positioning has not been established. 
However, alternative methods for positioning in obstetric patients include palpation of the 
balloon within the aorta during laparotomy or from measurements taken from a pre-operative 
MRI [42, 43]. Confirming catheter position with an x-ray limits radiation exposure to the fetus 
compared to the use of fluoroscopy. Any of these positioning methods can be performed in 
a standard operating room with a standard table. Additionally, the catheter can be inflated, 
deflated, and repositioned as needed throughout the case without the needing to move the 
patient or obtain additional imaging.
Previous cases of REBOA use in MAP procedures describe placement by an interventional 
radiologist, however fluoroscopy-free REBOAs in trauma patients are most commonly placed 
by surgeons or emergency medicine physicians (Table 3) [9, 10, 40, 42, 43, 47–50]. These pro-
viders are readily available in the hospital, allowing for expedient response times. REBOA 








Device used Image guidance
Zone 1 occlusion technique
Russo1 CR 1 Prophylactic 7Fr (Prytime) None
Zone 3 occlusion technique
Bell-Thomas2 CR 1 Reactive 10Fr (BVM 
Medical)
None
Luo3 CS 4 Prophylactic 10Fr (Cook) Fluoro
Masamoto4 CR 1 Prophylactic 5Fr (Sheft) Fluoro
Paull5 CR 1 Prophylactic 8.5Fr (Cook) Fluoro
Usman6 CR 1 Reactive NR None
Wei7 CS 3 Prophylactic 8Fr (Bard) Fluoro
Duan8 CS 4 Prophylactic 8Fr (Bard) Fluoro














Zone 1 Occlusion Technique
Russo1 32 3 None 4.2 5 None
Zone 3 Occlusion Technique
Bell-Thomas2 NR Massive >40 units 4 >60 Vesico-vaginal fistula
Luo3 NS 0.8 0.4 L 1.3 NR Ureteral damage ×2
Masamoto4 80 3.2 1.2 L NR NR None
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trained provider using the ER-REBOA catheter (Prytime Medical, Boerne, TX). In the future, 
REBOA can be used increasingly for both obstetric emergencies and complicated obstetric 
scenarios, such as a high-risk obstetric patient with MAP.
4.3. Risks and limitations
The risks and limitations of REBOA are still being described, and the relative incidence of 
each is not yet known. The majority of data published on this topic describes the application 
of REBOA in the trauma population that consists largely of male patients with concomitant 
hemorrhagic shock. Potential complications from REBOA include those related to arterial 
access, balloon positioning and inflation, and the physiologic changes that result from infla-
tion and deflation of the device (Table 4). From the trauma literature, access site complica-
tions are similar to those encountered during other forms of arterial puncture, but may be 
severe, including limb ischemia requiring amputation [51, 52]. Balloon malposition into an 
aortic branch vessel or migration into a higher or lower position within the aorta has also been 
described, sometimes resulting in uncontrolled arterial rupture and death [45, 51]. In animal 
models, proximal hypertension resulting from aortic occlusion has led to acute heart failure, 
cerebral edema, and respiratory failure [53, 54]. Distal organ ischemia during occlusion can 
lead to renal failure, bowel ischemia, and paralysis [51, 52]. Finally, washout of toxic metabo-
lites following balloon deflation can cause rebound hypotension with cardiac collapse [55].
The use of REBOA in obstetrics introduces a different patient population with other comor-
bidities and requires a different anatomic site of aortic occlusion. The ability to predict com-
plications for this population from the available trauma literature is therefore limited. The 
potential for severe complications exists and providers performing the procedure should be 
aware of these risks to improve patient management and the informed consent process.
The optimal location and duration of aortic occlusion is controversial. The primary blood 
supply to the gravid uterus includes the uterine arteries and collaterals from other branches 
of the internal iliac artery. However, particularly in cases of abnormal placentation, robust 














Paull5 NR 1.4 None NR 7 None
Usman6 NR Massive 40 units 6.5 9 NR
Wei7 NS 3.33 (2–6) 3.7 (2–7) NS NS NS
Duan8 22.4 0.6 0.4 L 1.1 5.5 None
Wu9 23.6 0.9 0.4 L 1.1 5.1 None
CR: case report; NR: not reported; CS: case series; NS: not specified (grouped in with other causes of hemorrhage).
Table 3. Previously reported obstetrical use of REBOA for MAP, 3A. Types of REBOA devices used, 3B. Surgical 
outcomes of REBOA use for MAP.
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reports of obstetric REBOA use describe occlusion in the infra-renal aorta (Zone 3). However, 
when Zone 3 occlusion is insufficient, supra-celiac (Zone 1) occlusion may further limit collat-
eral circulation through visceral and lumbosacral vessels and reduce venous back-bleeding. 
Caution should be used as Zone 1 occlusion is associated with more ischemic complications 
than Zone 3 occlusion [41]. Extrapolating from trauma literature, Zone 1 occlusion is tolerated 
for minutes, not hours, and multisystem organ failure and death have been reported after 
long inflation times [46, 52, 56]. In a prophylactic setting, the lack of pre-existing shock may 
improve ischemia tolerance and reduce the anticipated risks. However, there may still be a 
significant risk of supra-physiologic aortic pressure leading to heart failure [55].
4.4. Risk reduction
Risks of REBOA use can be reduced with multidisciplinary expertise, proper training, and 
adherence to good techniques. Low-profile, 7Fr common femoral arterial sheaths placed with 
ultrasound guidance have fewer access site complications than larger 12Fr sheaths. Additionally, 
distal thrombosis is rare with 7Fr sheaths and limb ischemia requiring amputation has not been 
reported. REBOA requires a dedicated provider to secure against catheter migration, manage 
inflation and deflation, and faithfully monitor the ipsilateral lower extremity for ischemia.
• Access site complications, including limb ischemia 
requiring amputation
• Use low-profile (7Fr) sheath
• Use ultrasound to obtain CFA access
• Monitor ipsilateral DP/PT pulses while the sheath is 
in place
• Consider heparin flushes
• Post-procedure angiography prior to sheath removal
• Balloon malposition or migration • Confirm balloon position with x-ray
• Secure catheter while in place
• Dedicated provider to maintain REBOA catheter/bal-
loon control
• Proximal hypertension that may lead to acute heart 
failure, cerebral edema or ARDS
• Close communication with anesthesia
• Concurrent administration of vasodilators while 
balloon inflated
• Reposition from Zone 1 to Zone 3 when able
• Minimize duration of occlusion
• Distal organ ischemia, that may cause renal failure, 
ischemic bowel, or paralysis
• Minimize duration of occlusion
• Reposition from Zone 1 to Zone 3 when able
• Institute partial or intermittent REBOA when able
• Washout of toxic metabolites, leading to rebound 
hypotension and cardiac instability
• Institute partial or intermittent REBOA when able
• Slowly, gradually deflate balloon
• Communicate with anesthesia
• Time administration of fluids, calcium, and pressors 
ith balloon deflation
Table 4. Risks of REBOA and methods of mitigation.
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During balloon inflation, the anesthesia team should work to off-set unwanted blood pressure 
augmentation and maintain normal physiologic pressures. The surgical teams should aim to 
achieve hemorrhage control rapidly to keep the duration of Zone 1 occlusion to a minimum. 
Other methods used to reduce ischemia include intermittent or partial balloon deflation and 
relocating the REBOA balloon to Zone 3 when able [55]. These techniques will allow some 
distal blood flow to perfuse ischemic tissues and prolong the overall duration of REBOA use. 
Providers should be aware that balloon deflation is associated with the rapid redistribution 
of circulating blood volume and the washout of ischemic metabolites, including a bolus of 
potassium, which can result in rebound hypotension and cardiac instability [55]. The combi-
nation of partial occlusion and relocation from Zone 1 to Zone 3, along with close communica-
tion with the anesthesia providers to time fluid and drug administration with inflation and 
deflation, can aid in maintaining hemodynamic stability throughout surgery.
There is a dearth of published information about management of intra-arterial balloons dur-
ing high-risk obstetric procedures. Of all reported cases, there has been only one documented 
aortic rupture due to a smaller than expected aortic diameter [45]. Few cases describe flushing 
the sheath or catheters, although doing so is a well-established principle of vascular surgery. 
Whether the flush solution should contain heparin is additionally controversial when these 
catheters are used for hemorrhage control in patients that cannot receive blood. The authors’ 
practice is to use 30 ml 2% heparin (2 units of heparin per 100 ml of crystalloid) through the 
sheath and another 30 ml through the central lumen of the REBOA catheter every 10 min-
utes, while monitoring thromboelastography to ensure the absence of systemic coagulopa-
thy. Frequent monitoring of distal pulses in the ipsilateral extremity should be maintained 
throughout the case and for 24 hours after sheath removal. Continuous Doppler may be a 
helpful adjunct to aid in early detection of arterial access complications.
The risks and benefits of anticoagulation deserve special consideration in this patient popula-
tion. Pregnancy itself confers a hypercoagulable state. These patients may be at even higher 
risk of clot formation due to the administration of TXA, erythropoietin, cryoprecipitate or 
other coagulation factors. Postoperatively, VTE risk remains high in the setting of immobility 
and/or symptomatic anemia. In the immediate postoperative period, the risk of death from 
hemorrhage may outweigh the risks from VTE. Within several days of surgery however, 
the probability of hemorrhage decreases, justifying prophylactic heparin administration to 
reduce the risk of VTE.
5. Future directions
REBOA is a novel, minimally-invasive method to control non-compressible hemorrhage. Much 
of the literature regarding techniques for placement and risks of use are derived male trauma 
patients. More research is needed to investigate the use of REBOA in a peripartum setting. 
Reports of prophylactic use of REBOA to minimize blood loss during high-risk obstetric opera-
tions, claim to reduce blood loss and improve rates of uterine salvage compared to other types 
of arterial occlusion techniques, such as hypogastric and uterine artery occlusion. Most of 
this evidence comes from retrospective case series out of Asia. Comparative data is needed to 
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examine the risks and benefits of REBOA compared to other methods of hemorrhage control 
utilized in the West. Although case reports and case series have shown that REBOA can suc-
cessfully provide temporary control of obstetric hemorrhage, up to three liters of blood loss 
has been reported in these cases despite aortic occlusion. Larger studies are needed to quantify 
the expected hemorrhage volume during aortic occlusion to help inform perioperative plans.
Furthermore, instructions on REBOA use and placement for the obstetric patient are extrapo-
lated from the trauma literature. Whether external landmarks on the gravid abdomen can be 
used reliably for positioning of REBOA has yet to be determined. More research is needed to 
establish whether imaging is needed to verify balloon position prior to inflation, and to assess 
the associated risk of radiation exposure to the fetus. The optimal zone of REBOA inflation 
is not known for obstetric hemorrhage. More research should focus on defining collateral 
pathways for circulation to the gravid uterus, especially in the case of abnormal placentation. 
Additionally, the effect of proximal vs. distal occlusion on blood pressure support during 
various stages of hemorrhagic shock should be established to aid in defining the optimal level 
of occlusion for initial balloon inflation in prophylactic and reactive settings.
Finally, the risks of REBOA are also generated from its reactive placement in trauma patients 
experiencing hemorrhagic shock. Although it can be assumed that prophylactic use of REBOA 
during planned obstetric procedures will have decreased risk compared to trauma situations, 
more research is needed to investigate this use of REBOA. As the adoption of REBOA for 
obstetric hemorrhage becomes more prevalent, it is expected that increasing evidence will 
help delineate more definitive guidelines for this population.
6. Recommendations
For high-risk patients with MAP, thorough planning throughout the prenatal period is critical 
to successful management. Prenatal optimization of hemoglobin and preoperative involvement 
of a multidisciplinary team can improve maternal outcomes. If blood products are not readily 
available or are declined by the patient, alternative options should be discussed. Clearly eliciting 
if blood fractions, clotting factors, and TXA will be accepted by the patient can assist in surgical 
planning. Meticulous surgical techniques and clear communication with the anesthesia team 
can minimize intraoperative hemorrhage. Additional adjuncts such as ANH and cell salvage 
may ease the effects of blood loss. Consideration of REBOA use may decrease the volume of 
blood lost and the need for transfusion. Planning for REBOA use in a proactive and prophylactic 
setting may limit the risks of the procedure and improve morbidity and mortality.
Implementing REBOA in the obstetric patient requires careful multidisciplinary management 
and clear communication throughout the perioperative period. General principles of vascular 
access should be respected. Minimizing the risk of limb ischemia requires selecting the small-
est sheath possible to accommodate the selected balloon catheter, frequent vascular checks 
of both lower extremities, consideration of post-procedural angiography, and prompt sheath 
removal. The duration of balloon inflation should be minimized, and intermittent or partial 
balloon deflation should be used as adjuncts to reduce ischemia when necessary. Anticipating 
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hemodynamic and metabolic changes associated with balloon inflation and deflation is para-
mount and requires frequent communication between the operating and anesthesia teams to 
time the administration of medications and fluids.
Finally, providing supportive care for profound anemia and limiting unnecessary lab draws 
can improve postoperative outcomes. Careful consideration must be given to the use and tim-
ing of anticoagulation in setting where further hemorrhage could be detrimental to patients. 
A summary of the recommendations can be found in Table 5.
7. Conclusions
In conclusion, women undergoing planned operations for MAP are among those at highest 
risk for catastrophic obstetric hemorrhage, especially those for whom blood products are not 
an option. A multidisciplinary approach to management is the key to patient survival. Goals 
include limiting blood loss, maintaining hemodynamic stability, and reducing postoperative 
morbidity. In addition to the obstetric and anesthesia teams, assistance by general, acute care, 
trauma, or vascular surgeons may be required for hemorrhage control. REBOA is an emerg-
ing hemorrhage-control technique with benefits for obstetric applications and represents a 
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• Assemble multidisciplinary team including all perioperative stakeholders
• Optimize preoperative blood volume and hemoglobin
• Plan risks and benefits discussion comparing available hemorrhage control adjuncts available at the institution
• Consider REBOA as an adjunct to temporary hemorrhage control
• Expeditiously achieve definitive hemorrhage control
• Provide post-operative intensive care, anticipating fluid shifts and electrolyte abnormalities associated with 
severe anemia and ischemia–reperfusion
Table 5. Summary recommendations.
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Acronyms and abbreviations
ANH acute normovolemic hemodilution
FVIII Factor VIII
MMR maternal mortality ratio
MAP morbidly adherent placenta
rFVIIa recombinant factor VIIa
REBOA resuscitative endovascular balloon occlusion of the aorta
TXA tranexamic acid
VTE venous thromboembolism
vWF Von Willebrand factor
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